The Selection and Use of Essential Medicines - WHO Technical Report Series, No. 920: References

The Selection and Use of Essential Medicines - WHO Technical Report Series, No. 920
(2003; 137 pages)

Table of Contents

1. Introduction
2. Open session
3. Update on current activities
	3.1 Dissemination of the previous report of the Expert Committee (including the 12th Model List)
	3.2 The twenty-fifth anniversary of the WHO Model List of Essential Medicines
	3.3 The WHO model formulary
	3.4 Review of the New Emergency Health Kit
	3.5 Review of essential medicines for reproductive health
	3.6 Report of an ad hoc Advisory Committee on priority vaccines
	3.7 The WHO Essential Medicines Library
	3.8 Promoting rational use of essential medicines
		3.8.1 Update on activities to contain antimicrobial resistance
		3.8.2 Guidelines for drugs and therapeutic committees
		3.8.3 WHO database on rational drug use studies
4. Changes made in revising the Model List
	4.1 Applications for additions
		4.1.1 Amodiaquine
		4.1.2 Azithromycin
		4.1.3 Ibuprofen (paediatric formulation)
		4.1.4 Insulin semilente
		4.1.5 Miconazole nitrate buccal tablets
		4.1.6 Misoprostol
		4.1.7 Valaciclovir
	4.2 Applications for deletions
		4.2.1 Ethinylestradiol + levonorgestrel tablets (50µg + 250µg, pack of four)
		4.2.2 Nonoxynol
	4.3 Applications for addition of information
		4.3.1 Anti-leprosy medicines
	4.4 Other changes
		4.4.1 Oral rehydration salts
		4.4.2 Streptokinase
5. Reviews of sections of the Model List
	5.1 "Fast-track" procedure for deleting items from the Model List
	5.2 Review of core versus complementary listing of medicines
	5.3 Review of the use of the square box symbol (including a review of the corticosteroids)
	5.4 Review of the antihypertensive medicines
6. Priorities for future reviews
7. Recommendations
	7.1 Additions, deletions and other changes to the Model List
	7.2 Core versus complementary listing of medicines
	7.3 Use of the square box symbol (including review of the corticosteroids
	7.4 Review of the antihypertensive medicines
	7.5 Future priorities
References
Annex 1 The 13th WHO Model List of Essential Medicines
Annex 2 The Anatomical Therapeutic Chemical (ATC) classification system¹
Alphabetical list of essential medicines (with ATC classification code numbers)
Selected WHO Publications of Related Interest

References

1. WHO model formulary 2002. Geneva, World Health Organization, 2002.

2. The selection and use of essential medicines. Report of the WHO Expert Committee, 2002 (including the 12th Model List of Essential Medicines). Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 914) (http://www.who.int/medicines/organization/par/edl/trs/trs914.shtml, accessed 3 October 2003).

3. The selection of essential drugs. Report of a WHO Expert Committee. Geneva, World Health Organization, 1977 (WHO Technical Report Series, No. 615).

4. Essential medicines as a global concept: 25 years commemorative event [CD-ROM]. Geneva, World Health Organization, 2003 (WHO/EDM/2003.3; http://www.who.int/medicines/organization/par/anniversary.shtml, accessed 3 October 2003).

5. Couper MR, Mehta D, eds. WHO model formulary 2002 [CD-ROM]. Geneva, World Health Organization, 2002.

6. The New Emergency Health Kit. Drugs and medical supplies for 10000 for approximately 3 months. Geneva, World Health Organization, 1998 (WHO/ DAP/98.10; available in English, French, Russian and Spanish; http://www.who.int/medicines/library/par/new-emergency-health-kit/nehken.shtml, accessed 3 October 2003).

7. Emergency relief items. Compendium of basic specifications, vol. 2. New York, NY, United Nations Development Programme, and Inter-agency Procurement Services, Copenhagen, 1999.

8. Resolution WHA51.17. Emerging and other communicable diseases: antimicrobial resistance. In: Fifty-first World Health Assembly, Geneva, 11-16 May 1998. Volume 1. Resolutions and decisions, annexes. Geneva, World Health Organization, 1998 (WHA51/1998/REC/1).

9. WHO global strategy for the containment of antimicrobial resistance. Geneva, World Health Organization, 2001 (WHO/CDS/CSR/DRS/2001.2; http://whqlibdoc.who.int/hq/2001/WHO_CDS_CSR_DRS_2001.2pdf, accessed 3 October 2003).

10. Drugs and therapeutics committees: a practical guide. Geneva, World Health Organization (in preparation).

11. The rational use of drugs. Report of the Conference of Experts, Nairobi, 25-29 November 1985. Geneva, World Health Organization, 1987.

12. The selection of essential drugs. Second report of a WHO Expert Committee. Geneva, World Health Organization, 1979 (WHO Technical Report Series, No. 641).

13. The use of essential drugs. Report of a WHO Expert Committee. Geneva, World Health Organization, 1983 (WHO Technical Report Series, No. 685).

14. The use of essential drugs. Model list of essential drugs (fifth list). Third report of the WHO Expert Committee. Geneva, World Health Organization, 1988 (WHO Technical Report Series, No. 770).

15. Church LWP et al. Clinical manifestations of P. falciparum malaria experimentally induced by mosquito challenge. Journal of Infectious Diseases, 1997, 175:915-920.

16. Dale DC, Wolff SM. Studies of the neutropenia of acute malaria. Blood, 1973, 41:197-206.

17. Richter B, Neises G. "Human" insulin versus animal insulin in people with diabetes mellitus [abstract]. In: The Cochrane Library [online database and CD-ROM], Issue 1. Oxford, Update Software, 2003, Issue 3:ab003816 (http://www.update-software.com/abstracts/ab003816.htm).

18. RE Resolution, number 905, 21 June 2001. Brasília, DF. National Health Surveillance Agency (ANVISA). [Published 22 June 2001 in the National Official Journal (DOU)] (http://www.anvisa.gov.br/eng/legis/index.htm).

19. Grant DM et al. Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model. Pharmacotherapy, 1997, 17:333-341.

20. Ho PC, Kwan MSW. A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception. Human Reproduction, 1993, 8:389-392.

21. Cheng L et al. Interventions for emergency contraception [abstract]. In: The Cochrane Library [online database and CD-ROM], Issue 1. Oxford, Update Software, 2003:AB001324 (http://www.update-software.com/abstracts/ab001324.htm).

22. Task Force on Post-ovulatory Methods of Fertility Regulation. Randomized controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet, 1998, 352:428-433.

23. von Hertzen H et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomized trial. Lancet, 2002, 360:1803-1810.

24. WHO/CONRAD Technical Consultation on nonoxynol-9. Summary report. Geneva, 9-10 October 2001. Geneva, World Health Organization, 2002 (http://www.who.int/reproductive-health/rtis/honoxynol9.html, accessed 8 October 2003).

25. van Damme L et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-transmission among female sex workers. Lancet, 2002, 360:971-977.

26. Wilkinson D et al. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomized controlled trials including more than 5000 women. Lancet Infectious Diseases, 2002, 2:613-617.

27. The male latex condom. Geneva, Joint United Nations Programme on HIV/ AIDS, 1998 (WHO/RHT/FPP/98-15)..

28. Bounds W et al. The diaphragm with and without spermicide. A randomized, comparative efficacy trial. Journal of Reproductive Medicine, 1995, 40:764-774.

29. Reduced osmolarity oral rehydration salts (ORS) formulation. Consensus statement of WHO and UNICEF. Geneva, World Health Organization, 2001 (WHO/FCH/CAH/01.22; http://www.who.int/child-adolescent-health/New_Publications/NEWS/Expert_consultation.htm, accessed 4 October 2003).

30. Cancer pain relief: with a guide to opioid availability, 2nd ed. Geneva, World Health Organization, 1996.

31. Hughes E, Collins J, Vandekerckhove P. Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea [abstract]. In: The Cochrane Library [online database and CD-ROM], Issue 1. Oxford, Update Software, 2003:AB000056 (http://www.update-software.com/abstracts/ab000056.htm).

32. Cold and cough remedies for the treatment of acute respiratory infections in young children. Geneva, World Health Organization, 2001 (document WHO/ FCH/CAH/01.02; http://www.who.int/child-adolescent-health/New_Publications/CHILD_HEALTH/WHO_FCH_CAH_01.02.pdf, accessed 6 October 2003).

33. Schroeder K, Fahey T. Over-the-counter medications for acute cough in children and adults in ambulatory settings (Cochrane Review). In: The Cochrane Library [CD-ROM], Issue 1. Oxford, Update Software, 2003:AB001831.

34. Suarez-Almazor ME et al. Cyclophosphamide for treating rheumatoid arthritis [abstract]. In: The Cochrane Library [online database and CD-ROM], Issue 1. Oxford, Update Software, 2003:AB001157 (http://www.update-software.com/abstracts/ab001157.htm).

35. Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: a manual for a drug regulatory authority. Geneva, World Health Organization, 1999 (document WHO/DMP/RGS/98.5; Regulatory Support Series, No.5).

36. WHO/ISH guidelines for the management of hypertension. Geneva, World Health Organization, 1999 (withdrawn).

37. Probstfield JL. Prevention of stroke by antihypertensive treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). Journal of the American Medical Association, 1991, 265:3255-3264.

38. Cushman WC et al. Regional and racial differences in response to antihypertensive medication use in a randomised controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Archives of Internal Medicine, 2000, 160:825-831.

39. Manyeba J et al. Reserpine for hypertension (Protocol for a Cochrane Review). In: The Cochrane Library [online database and CD-ROM], Issue 3. Oxford, Update Software, 2003.

40. Pillay A, O'Reagan L. Methyldopa in the management of essential hypertension (Protocol for a Cochrane Review). In: The Cochrane Library [online database and CD-ROM], Issue 3. Oxford, Update Software, 2003.

41. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker or vs diuretic: The Anti-Hypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial. Journal of the American Medical Association, 2002, 288:2981-2997.

42. Abólos E et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy (Cochrane Review). In: The Cochrane Library [CD-ROM], Issue 3. Oxford, Update Software, 2003:AB002252.

43. Duley L, Henderson-Smart DJ. Drugs for the treatment of very high blood pressure during pregnancy [abstract]. In: The Cochrane Library [online database and CD-ROM], Issue 3. Oxford, Update Software, 2003:AB001449 (http://www.update-software.com/abstracts/ab002252.htm).

44. Elhassan EM et al. Methyldopa versus no drug treatment in the management of mild pre-eclampsia. East African Medical Journal, 2002, 79:172-175.

45. The MAGPIE Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The MAGPIE Trial: a randomised placebo-controlled trial. Lancet, 2002, 359:1877-1890.

46. Duley L, Gülmezoglu AM, Henderson-Smart DJ. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia [abstract]. In: The Cochrane Library [online database and CD-ROM], Issue 1. Oxford, Update software, 2004:ab000025. (http://212.49.218-202/abstracts/ab000025.htm).